Fr280 GASTRODUODENAL EOSINOPHILIA AND MAST CELLS IN FUNCTIONAL GASTROINTESTINAL DISEASES (FUNCTIONAL DYSPEPSIA AND IRRITABLE BOWEL SYNDROME): A META-ANALYSIS

2021 ◽  
Vol 160 (6) ◽  
pp. S-282
Author(s):  
Georgia Brown ◽  
Kerith Duncanson ◽  
Guy D. Eslick ◽  
Michael P. Jones ◽  
Marjorie M. Walker ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Mast Cells ◽  
Functional Dyspepsia ◽  
Meta Analysis ◽  
Gastrointestinal Diseases ◽  
Irritable Bowel ◽  
Functional Gastrointestinal Diseases

scholarly journals Current Prospects of Herbal STW 5 Agent in Treatment of Functional Gastrointestinal Diseases

2022 ◽  
Vol 31 (5) ◽  
pp. 61-65
Author(s):  
A. A. Sheptulin
Keyword(s):  
Irritable Bowel Syndrome ◽  
Functional Dyspepsia ◽  
Treatment Efficacy ◽  
Gastrointestinal Diseases ◽  
Mechanisms Of Action ◽  
Current Evidence ◽  
Key Points ◽  
Irritable Bowel ◽  
Functional Gastrointestinal Diseases ◽  
Agent Development

Aim. A review of current therapeutic perspectives of the herbal STW 5 medicine (Iberogast®) in functional gastrointestinal (GI) diseases.Key points. A limited remediation in most common functional GI diseases, functional dyspepsia (FD) and irritable bowel syndrome (IBS), is conditioned by their multifactorial pathogenesis. Meanwhile, most specific medicines only target selected pathogenesis components, thus warranting a multitarget agent development. Such is Iberogast® that acts at variant components of FD and IBS pathogenesis. The article reviews the Iberogast® mechanisms of action and evaluates its treatment efficacy in FD and IBS.Conclusion. The current evidence claims that Iberogast® provides an effective and safe treatment for FD and IBS. 

Mucosal Mast Cells Are Increased in the Small Intestine of Patients With Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S261-S262
Author(s):  
Pavid Perez Ingles ◽  
Abhizith Peoker ◽  
Alejandro Robles ◽  
Jerzy Sarosiek ◽  
Richard McCallum ◽  
...  
Keyword(s):  
Systematic Review ◽  
Irritable Bowel Syndrome ◽  
Small Intestine ◽  
Mast Cells ◽  
Meta Analysis ◽  
Mucosal Mast Cells ◽  
Irritable Bowel

scholarly journals Overlap of functional dyspepsia and irritable bowel syndrome by revised Rome IV criteria: meta-analysis

2021 ◽  
pp. 12-20
Author(s):  
I. V. Maev ◽  
R. M. Umyarova ◽  
D. N. Andreev ◽  
E. S. Vyuchnova ◽  
E. G. Lebedeva ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Functional Dyspepsia ◽  
Random Effects ◽  
Meta Analysis ◽  
Clinical Manifestations ◽  
Final Analysis ◽  
Significant Heterogeneity ◽  
Random Effects Model ◽  
Irritable Bowel ◽  
Rome Iv

Introduction. Functional dyspepsia (FD) and irritable bowel syndrome (IBS) overlap is an adverse clinical situation, as patients with this syndrome have more severe clinical manifestations resulting in significant reductions in quality of life. For now, there are no meta-analytical papers that would summarize the frequency of FD – IBS overlap using the revised Rome IV criteria. Objective. To organize data on the prevalence of FD – IBS overlap using the revised Rome IV criteria.Materials and methods. A search for studies was conducted in MEDLINE / PubMed, EMBASE, Cochrane electronic databases. The search depth was 6 years (from January 2016 to February 2021). The final analysis included original publications from peerreviewed periodicals that used the revised Rome IV criteria as a method for diagnosing FD and IBS in the adult population with detailed descriptive statistics allowing to include resulting data in the meta-analysis.Results and discussion. The final analysis included 6 studies involving 1,180 patients with PD and 600 patients with IBS. The generalized prevalence of IBS in patients with PD was 41.511% (95% CI: 22.203–62.288). The analysis was undertaken by using a random-effects model, as there was significant heterogeneity among results (p < 0.0001; I2 = 94.28%). The generalized prevalence of PD in patients with IBS was 38.791% (95% CI: 9.438–73.710). The analysis was undertaken by using a random-effects model, as there was significant heterogeneity among results (p < 0.0001; I2 = 99.25%).Сonclusion. The complete meta-analysis showed that the frequency of FD - IBS overlap using the revised Rome IV criteria is quite high and accounts for about 40%. At the same time, further large studies of more homogeneous structure are needed to verify these results and study the potential pathogenetic relationship between PD and IBS. 

scholarly journals An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome

2021 ◽  
Vol 12 ◽  
Author(s):  
Zhang Zhen ◽  
Lin Xia ◽  
Huang You ◽  
Zhou Jingwei ◽  
Yang Shasha ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Clinical Effect ◽  
Gastrointestinal Diseases ◽  
The Body ◽  
Network Pharmacology ◽  
Ifn Γ ◽  
Irritable Bowel ◽  
D Model ◽  
Functional Gastrointestinal Diseases

Diarrhea-predominant irritable bowel syndrome (IBS-D) is one of the most common chronic functional gastrointestinal diseases with limited treatments. Gut microbiota play an important role in chronic gastrointestinal diseases. In traditional Chinese medicine (TCM), Spleen–Yang deficiency (SYD) is one of the root causes of IBS-D. Fuzi-Lizhong pill (FLZP) is well known for its powerful capacity for treating SYD and has a good clinical effect on IBS-D. However, the mechanism of FLZP on the gut microbiota of IBS-D has not been fully clarified. Our present study aimed to reveal the mechanism of FLZP regulating gut microbiota of IBS-D. The body mass, CCK, MTL, and Bristol fecal character score were used to verify the establishment of the IBS-D model. IL-6, TNF, IL-1β, and IFN-γ were crucial targets screened by network pharmacology and preliminarily verified by ELISA. Eighteen gut microbiota were important for the treatment of IBS-D with FLZP. Bacteroidetes, Blautia, Turicibacter, and Ruminococcus_torques_group were the crucial gut microbiota that FLZP inhibits persistent systemic inflammation in the IBS-D model. Lactobacillus is the crucial gut microbiota that FLZP renovates intestinal immune barrier in the IBS-D model. In summary, FLZP can affect bacterial diversity and community structures in the host and regulate inflammation and immune system to treat IBS-D.

Sign in / Sign up

Export Citation Format

Share Document